129 related articles for article (PubMed ID: 420952)
1. Ara-C metabolism: implications for drug resistance and drug interactions.
Chabner BA; Hande KR; Drake JC
Bull Cancer; 1979; 66(1):89-92. PubMed ID: 420952
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
Avramis VI; Powell W
Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
[TBL] [Abstract][Full Text] [Related]
3. Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.
Kreis W; Hession C; Soricelli A; Scully K
Cancer Treat Rep; 1977 Oct; 61(7):1355-64. PubMed ID: 589601
[TBL] [Abstract][Full Text] [Related]
4. Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man.
Kreis W; Woodcock TM; Gordon CS; Krakoff IH
Cancer Treat Rep; 1977 Oct; 61(7):1347-53. PubMed ID: 589600
[TBL] [Abstract][Full Text] [Related]
5. Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblast and hematopoietic cells.
Momparler RL; Eliopoulos N; Bovenzi V; Létourneau S; Greenbaum M; Cournoyer D
Cancer Gene Ther; 1996; 3(5):331-8. PubMed ID: 8894252
[TBL] [Abstract][Full Text] [Related]
6. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
Li ZR; Campbell J; Rustum YM
Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
[TBL] [Abstract][Full Text] [Related]
7. Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
Grant S; Bhalla K; McCrady C
Leuk Res; 1991; 15(4):205-13. PubMed ID: 2030601
[TBL] [Abstract][Full Text] [Related]
8. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
Gandhi V; Xu YZ; Estey E
Clin Cancer Res; 1998 Jul; 4(7):1719-26. PubMed ID: 9676847
[TBL] [Abstract][Full Text] [Related]
9. Formation of cytosine arabinoside-5'-triphosphate in cultured human leukemic cell lines correlates with nucleoside transport capacity.
Tanaka M; Yoshida S
Jpn J Cancer Res; 1987 Aug; 78(8):851-7. PubMed ID: 3115933
[TBL] [Abstract][Full Text] [Related]
10. Effect of tetrahydrouridine on metabolism and transport of 1-beta-D-arabinofuranosylcytosine in human cells.
Riva C; Barra Y; Carcassonne Y; Cano JP; Rustum Y
Chemotherapy; 1992; 38(5):358-66. PubMed ID: 1286578
[TBL] [Abstract][Full Text] [Related]
11. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase.
Laliberté J; Marquez VE; Momparler RL
Cancer Chemother Pharmacol; 1992; 30(1):7-11. PubMed ID: 1375134
[TBL] [Abstract][Full Text] [Related]
12. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
Chandrasekaran B; Capizzi RL; Kute TE; Morgan T; Dimling J
Cancer Res; 1989 Jun; 49(12):3259-66. PubMed ID: 2720678
[TBL] [Abstract][Full Text] [Related]
13. Selection of drug-resistant transduced cells with cytosine nucleoside analogs using the human cytidine deaminase gene.
Beauséjour CM; Eliopoulos N; Momparler L; Le NL; Momparler RL
Cancer Gene Ther; 2001 Sep; 8(9):669-76. PubMed ID: 11593336
[TBL] [Abstract][Full Text] [Related]
14. Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine.
Riccardi R; Chabner B; Glaubiger DL; Wood J; Poplack DG
Cancer Res; 1982 May; 42(5):1736-9. PubMed ID: 6896013
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside.
Chabot GG; Bouchard J; Momparler RL
Biochem Pharmacol; 1983 Apr; 32(7):1327-8. PubMed ID: 6189497
[No Abstract] [Full Text] [Related]
16. [Mice transduced with double-mutant dihydrofolate reductase-cytidine deaminase fusion gene attained protection from high dose chemotherapy].
Lu P; Lu Y; Pang K; Wang SB; Chen JQ; Xu HM; Wang JK; Zhao SC
Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):998-1001. PubMed ID: 16194358
[TBL] [Abstract][Full Text] [Related]
17. [Chemotherapy of the malignancies from the viewpoint of pharmacology and biochemistry of cytosine arabinoside (ara-C) and its derivatives].
Nakamura T; Ueda T
Gan To Kagaku Ryoho; 1982 Aug; 9(8):1339-51. PubMed ID: 6191711
[TBL] [Abstract][Full Text] [Related]
18. Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside.
Wong PP; Currie VE; Mackey RW; Krakoff IH; Tan CT; Burchenal JH; Young CW
Cancer Treat Rep; 1979 Aug; 63(8):1245-9. PubMed ID: 383291
[TBL] [Abstract][Full Text] [Related]
19. Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells.
Eliopoulos N; Cournoyer D; Momparler RL
Cancer Chemother Pharmacol; 1998; 42(5):373-8. PubMed ID: 9771951
[TBL] [Abstract][Full Text] [Related]
20. Labelling of the thymidine and deoxycytidine bases of DNA by [2-14C]deoxycytidine in cultured L1210 cells.
Karle JM; Hoerauf RM; Cysyk RL
Cancer Lett; 1983 Jun; 19(2):147-57. PubMed ID: 6883305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
